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Background
Eliciting broad cross neutralizing antibodies (bNAb)
remains the primary and most challenging goal in HIV-
1 vaccine development. So far no vaccine candidate has
induced such bNAb. Selecting Env vaccine candidates
will require both antigenic and immunogenic optimiza-
tion and testing in relevant animal models.
Methods
Based on in-vitro neutralizing activity in serum, patients
(n=6, subtype A and B infected) were selected and Env
sequences of early HIV-1 variants, still sensitive to auto-
logous neutralization, were used to generate soluble Env
as immunogens. Gp140 trimeric proteins were expressed
(293T cells) and purified. Rabbits (4/group) were immu-
nized s.c. at weeks 0, 2, 4, 8 with 100µg trimer adju-
vanted with cationic CAF01. Control groups received
20µg and 100µg trimer plus/minus CAF01 respectively.
Sera collected at weeks 0, 2, 4, 8, 12 and 14 were
screened in gp120-IIIB ELISA and IgG was analyzed in
the TZMbl neutralization assay.
Results
All rabbits generated a gp120-IIIB specific IgG response
2 weeks after the first immunization and titers were
boosted after each subsequent immunization. IgG titers
measured 4 weeks after the last immunization clearly
differed between groups (n=5) receiving 100µg/immuni-
zation (Geometric mean titer (GMT) : 152.601) and the
group receiving 20µg/immunization (GMT : 13.262) or
the group omitting CAF01 (GMT : 27.262). Only IgG
from rabbits receiving the highest dose and in the
presence of CAF01 were able to neutralize Tier 1 pseu-
doviruses of different subtypes.
Neutralizing activity was detected after the 2nd immu-
nization and was boosted after each immunization. No
significant differences were observed between the differ-
ent trimers.
Conclusion
Gp140 trimers based on HIV-1 variants of patients with
bNAb in serum elicited gp120-IIIB specific IgG and
NAb given that enough immunogen was administrated
in the presence of CAF01. These results indicate that
the development of HIV-1 Env specific NAb is dose
dependent and strengthen the rabbit model for HIV
vaccine studies.
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